Nature published a study showing a CRISPR-Cas12a2 system selectively killed p53-mutant cancer cells by shredding chromatin after detecting mutant p53 mRNA, with efficacy in mouse lung and liver tumor models.
The approach aims at one of cancer therapy’s hardest targets: p53 mutations appear in nearly half of all cancers and in 70%–90% of some deadliest tumors, yet no approved p53 drug exists.
Zeng said the system can distinguish healthy from diseased cells differing by a single nucleotide, offering a way to hit cancer-specific mutations without correcting each mutation individually.
The team is now working on the main hurdle for CRISPR cancer therapies—delivery into tumors—and is exploring broader use in brain, prostate and ovarian cancers, with multiplexing potential across multiple mutations.
This new CRISPR therapy shreds cancer cells while sparing healthy ones. When might this 'no side effect' treatment reach human trials?
For decades, half of all cancers have been 'undruggable'. Can this new RNA-targeting 'genome shredder' finally conquer them?
Beyond cancer, could this cell-killing technology be programmed to fight viruses like HIV or even the effects of aging?
CRISPR-Cas12a2 Enables Programmable, RNA-Guided Cancer Cell Elimination: Breakthroughs and Barriers to Clinical Use
Overview
In 2026, groundbreaking research published in Nature introduced CRISPR-Cas12a2 as a new tool for precision cancer treatment. This breakthrough began when Jingkun Zeng joined Jennifer Doudna’s lab in 2024, focusing on stopping cancer progression. Recognizing that cancer’s complexity made traditional gene-by-gene correction impractical, Zeng and the team developed a Cas12a2-based strategy that targets unique RNA signatures found only in malignant cells. This approach allows Cas12a2 to eliminate cancer cells, including those with previously 'undruggable' mutations like in the p53 gene, marking a major shift in precision oncology and opening new possibilities for effective cancer therapies.